Axitinib, identified by the Chemical Abstracts Service (CAS) number 319460-85-0, stands as a vital active pharmaceutical ingredient (API) intermediate. This compound is widely recognized for its pivotal role in the development of targeted therapies designed to combat various forms of cancer. As a pharmaceutical raw material, Axitinib is typically supplied as a solid powder, crucial for subsequent formulation into medicinal products.

The significance of Axitinib powder in oncology cannot be overstated. It functions primarily as a potent inhibitor of multiple receptor tyrosine kinases (RTKs), particularly vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. By blocking these receptors, Axitinib interferes with the processes of angiogenesis, which is the formation of new blood vessels that tumors rely on to grow and spread. This targeted approach represents a cornerstone in modern cancer treatment strategies, offering more precise intervention with potentially fewer systemic side effects compared to traditional chemotherapy.

For pharmaceutical manufacturers, securing a supply of high-quality Axitinib CAS 319460-85-0 is paramount. The quality of the raw material directly impacts the efficacy, safety, and stability of the final drug product. Therefore, rigorous quality control and adherence to international standards are non-negotiable. Reputable suppliers and manufacturers ensure that their Axitinib powder meets stringent specifications regarding purity, physical characteristics, and chemical composition.

Typical specifications for high-grade Axitinib powder include a defined appearance, often described as a white to light-yellow solid powder. Identification tests utilizing techniques such as Infrared (IR) spectroscopy and High-Performance Liquid Chromatography (HPLC) are standard procedures to confirm the compound's identity. Solubility profiles are also important, with Axitinib typically soluble in solvents like DMSO, slightly soluble in water and ethanol, and practically insoluble in others like methanol and DMF.

Key analytical parameters are meticulously checked to ensure quality. These include Loss on Drying (LOD), Residue on Ignition, and Heavy Metal content, all of which must fall below specified limits to minimize potential contaminants. Crucially, the purity of Axitinib is assessed through assays and related substance testing. A high-purity API, often exceeding 99.0% on an anhydrous basis, with minimal individual or total impurities, is essential for pharmaceutical use. Bulk density is another physical characteristic monitored to ensure consistency in handling and processing during formulation.

Compliance with pharmaceutical quality management systems such as GMP (Good Manufacturing Practice), ISO (International Organization for Standardization), and capabilities aligned with FDA requirements are indicators of a reliable Axitinib manufacturer. These certifications reflect a commitment to quality throughout the manufacturing process, from raw material sourcing to the final API production. A robust quality system ensures traceability, consistency, and the integrity of the product batches.

Sourcing Axitinib CAS 319460-85-0 involves careful consideration of several factors. The reliability and production capacity of the Axitinib supplier are critical for maintaining a stable supply chain, essential for uninterrupted drug production. Manufacturers need partners who can consistently deliver high-purity material in required quantities, whether it's grams for R&D or kilograms for commercial production.

Considerations around Axitinib price are also a significant aspect of procurement. While cost-effectiveness is important, it must always be balanced against the assurance of quality. Compromising on the purity or quality standards of the raw material can lead to significant issues in drug development and production, including failed batches, regulatory hurdles, and ultimately, compromised patient safety and treatment efficacy. Therefore, purchasing decisions should be based on a comprehensive evaluation of quality, reliability, and cost.

Pharmaceutical companies looking to buy Axitinib should engage with suppliers who provide detailed documentation, including Certificates of Analysis (CoA), Material Safety Data Sheets (MSDS), and technical support. This ensures transparency and helps facilitate regulatory submissions for the final drug product. The process to purchase Axitinib often involves rigorous supplier qualification procedures, including audits, to verify manufacturing capabilities and quality systems.

Proper storage conditions for Axitinib powder are also vital for maintaining its stability and potency over time. The material should be preserved in tight, light-resistant containers and stored in a cool place, protecting it from degradation caused by moisture, light, and temperature fluctuations. Adherence to recommended storage guidelines is a key responsibility of both the supplier during transport and storage, and the manufacturer upon receipt.

The demand for high-quality anti-cancer APIs like Axitinib continues to grow as targeted therapies become more prevalent in oncology. The availability of a reliable source of Axitinib CAS 319460-85-0 powder is therefore crucial for the pharmaceutical industry to meet the needs of patients worldwide. Companies involved in the synthesis and supply of this critical raw material play an indispensable role in the global fight against cancer.

In conclusion, Axitinib powder, identified by CAS 319460-85-0, is a foundational component for producing life-saving anti-cancer medications. Its high purity, adherence to strict quality standards, and targeted mechanism of action make it invaluable. Establishing relationships with a trustworthy Axitinib manufacturer and reliable Axitinib supplier is paramount for pharmaceutical companies. Factors such as Axitinib price, quality documentation, and production capacity are key considerations when looking to buy Axitinib or purchase Axitinib for commercial scale production. The integrity of the supply chain for this vital API directly contributes to advancing cancer treatment outcomes.